Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06187402 · ClinicalTrials.gov registry record · Phase 1
A Study of LM-24C5 For Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by LaNova Medicines Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 6
- Study locations
NCT06187402: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by LaNova Medicines Limited.
NCT06187402 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by LaNova Medicines Limited. The registered enrollment target is 49 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (75% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06187402, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by LaNova Medicines Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 6
- Study locations
Study Summary
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Primary Outcome
Phase 1
Conditions Studied
Interventions
- DRUG LM-24C5
Study Locations (6)
California
- University of Southern California (USC) - Norris Comprehensive Cancer Center - Los Angeles
Florida
- Ocala Oncology - Ocala
Indiana
- Indiana University Melvan and Bren Simon Cancer Center - Indianapolis
Ohio
- The Christ Hospital - Cincinnati
Texas
- Mary Crowley Cancer Research Center - Dallas
Virginia
- Virginia Cancer Specialists, P.C. - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
What NCT06187402 shows while recruiting
NCT06187402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which LM-24C5 is the first listed.
NCT06187402 lists 6 locations in 6 states (California, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT06187402 about?
NCT06187402 is a clinical study titled "A Study of LM-24C5 For Advanced Solid Tumors". To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
What is the current status of trial NCT06187402?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2023-12-20. Estimated completion is 2026-12-30.
What conditions does trial NCT06187402 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06187402?
The interventions under investigation include: LM-24C5 (DRUG).
Who is sponsoring clinical trial NCT06187402?
This trial is sponsored by LaNova Medicines Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06187402 being conducted?
This trial has 6 study locations across California, Florida, Indiana, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06187402's enrollment target sits among peer trials
49 162nd of 189 higher than 28 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI